Development of the new antimalarial drug pyronaridine: a review.

Abstract

This report outlines the structure scheme and development of a new antimalarial drug pyronaridine, which was synthesized from either 2-aminopyridine or pyridine. A series of in vivo and in vitro experimental studies and the assessment of toxicity revealed pyronaridine to be a promising agent against erythrocytic stage of malaria parasites. It exhibited low toxicity and had no cross-resistance to chloroquine. Clinical administration in malaria cases showed high efficacy and mild side-effects. In order to retard the development of resistance of Plasmodium falciparum to pyronaridine, a combination of pyronaridine/sulfadoxine/pyrimethamine was used in the treatment of chloroquine-resistant falciparum malaria in Hainan Province. Further in vivo test was carried out to monitor the sensitivity of P. falciparum to this combined formula for 5 years (1986-1990) in Diaoluo area where chloquine-resistant falciparum malaria was prevalent. Drug resistance was not demonstrated in this field study.

• Authors: C Chen, X Zheng
• Journal: Biomedical and environmental sciences : BES (Biomed Environ Sci) Vol. 5 Issue 2 Pg. 149-60 (Jun 1992) ISSN: 0895-3988 [Print] China
• PMID: 1642789 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Review)

Chemical References

• Antimalarials
• Naphthyridines
• Sulfadoxine
• Chloroquine
• pyronaridine
• Pyrimethamine

Topics

• Administration, Oral
• Animals
• Antimalarials (administration & dosage, adverse effects, chemistry)
• Cardiovascular System (drug effects)
• Chloroquine (therapeutic use)
• Dogs
• Drug Evaluation
• Drug Evaluation, Preclinical
• Drug Resistance
• Drug Therapy, Combination
• Haplorhini
• Humans
• Injections, Intramuscular
• Lethal Dose 50
• Malaria, Falciparum (drug therapy)
• Mice
• Naphthyridines (administration & dosage, adverse effects, chemistry)
• Pyrimethamine (administration & dosage)
• Rabbits
• Sulfadoxine (administration & dosage)